Covid vaccines and antibodies therapies set up by AstraZeneca

Following a series of setbacks during the pandemic, AstraZeneca announced on Tuesday that it is forming a separate division for vaccines and antibody therapeutics to focus on the COVID-19 vaccine and the development of coronavirus treatments.
According to Reuters, the Anglo-Swedish firm was looking into possibilities for its vaccine business in July and intended to have more information by the end of 2021.

The new division, which will be led by executive vice-president of Europe and Canada, Iskra Reic, will combine research and development, manufacturing, commercial and medical teams, a company spokesperson said.

“The team will be dedicated to our COVID-19 vaccine, our long-acting antibody combination and our developmental vaccine addressing multiple variants of concern, as well as to our existing portfolio for respiratory viral disease,” the spokesperson said.

The decision to set up a new business comes after a tumultuous 18 months for the drug maker, which developed its COVID-19 vaccine in conjunction with Oxford University.

Production problems forced the company to cut deliveries to the European Union this year, prompting the bloc to launch a legal challenge. Governments have also restricted its use among certain age groups due to links to rare blood clots and its application for U.S. approval is taking longer than expected.

But positive results from trials of its antibody cocktail as a preventative shot against COVID-19 have given the company a major boost, potentially positioning it as a supplier of both COVID-19 vaccines and treatments.

The move indicates AstraZeneca sees a future for its COVID-19 shot beyond the pandemic but shouldn’t be taken as a sign it is planning a full-scale entry into the broader vaccine market, Hargreaves Lansdown analyst Nicholas Hyett said.

“That would require significant new research and development investment, and as yet we have no indication that this is forthcoming,” he said.

AstraZeneca has pledged to supply vaccines at cost during the pandemic. The not-for-profit strategy and challenges with the shot fuelled speculation about whether it would want to keep the business in the long term.

While AstraZeneca’s COVID-19 vaccine remained a drag on profits in the second quarter, sales of the shot more than tripled to $894 million from the first three months of the year, making it one of the company’s best-selling products.

Medically Speaking

Recent Posts

Harness the Power of Rice Water

Rice water, rich in inositol, antioxidants, vitamins, and minerals, protects hair from sunlight damage and…

6 hours ago

“8 Powerful Herbs and Supplements to Beat Bloating and Boost Your Gut Health Naturally”

Natural Remedies for Bloating: 8 Herbs and Supplements That Work Wonders for Your Gut Health…

6 hours ago

“Unlock the Power of Oil Pulling: Discover How This Simple Practice Improves Oral Health and Freshens Your Breath”

Benefits of Oil Pulling: Stops Bad Breath, Keeps Gums Healthy, But Can't Replace Brushing Oil…

6 hours ago

WHY DO YOU EXPERIENCE RUNNY NOSE AFTER EATING SPICY FOOD?

Spicy food – whether it’s a dash of chili in your curry, a spoonful of…

7 hours ago

“4 Simple Tests to Spot Adulterated Wheat Flour: Protect Your Health with These Easy Checks”

How To Identify Adulterated Wheat Flour? Try These 4 Easy Tests Wheat flour is a…

7 hours ago

“Unlock the Power of Jaggery: 10 Surprising Health Benefits of Eating It After Every Meal”

Reasons That Will Make You Eat Jaggery After Every Meal (Potential Health Benefits Inside) Jaggery,…

7 hours ago